Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Inclusion Criteria: * Histologic pathological or cytological diagnosis of squamous cell carcinoma of esophagus * Age ranges from 18 to 70 years * Patients must not have received any prior anticancer therapy * Preoperative stage cT2N+M0, cT3-4aN0/N+M0 thoracic esophageal squamous cell carcinoma evaluated by MDT consultation based on imaging examinations * Eastern cooperative oncology group (ECOG) performance status of 0 to 1 * Signed informed consent document on file * Females with childbearing potential must have a negative serum pregnancy * Adequate organ function to receive esophagectomy including the following: Bone marrow: absolute white blood cells count ≥3.0×10\^9/L, absolute neutrophil count (ANC) ≥1.5×10\^9/L, platelets ≥100×10\^9/L, haemoglobin ≥90g/L; Hepatic: total bilirubin ≤1.5 times upper limit of normal (ULN), alanine transaminase (ALT) and aspartate transaminase (AST) ≤2.5 times ULN; Renal: calculated creatinine clearance rate≥80ml/min * For childbearing potential males and females, who have agreed with contraception from start of investigational drug administration to 6 months after last dose of investigational drug * Patients who have no contraindication of nab-paclitaxel, cisplatin or capecitabine Exclusion Criteria: * Patients who may develop tracheoesophageal fistula or aortoesophageal fistula * Patients who have received allogeneic organ or stem cell transplants * Patients with uncontrolled diabetes mellitus, any serious or unstable medical condition or mental illness * Patients with preexisting or a history of ≥ Grade II peripheral neuropathy * Pregnant or breast feeding * Patients who take part in clinical trials of other drugs or biological therapy within 4 weeks before enrollment * Prior invasive malignancy in 5 years (except for curable carcinoma in situ of cervix and non-melanoma skin cancer) * Patients with digestive tract obstruction or metabolic dysfunction which may influence oral absorption of capecitabine * Patients with supraclavicular lymph node metastasis, celiac lymph node metastasis except for pericardial and left gastric lymph node metastasis * Patients with evidence of distant metastases